Biofrontera starts patient recruitment for U.S. Phase III Trial Evaluating Ameluz® / BF-RhodoLED® for Superficial Basal Cell Carcinoma
26 sept. 2018 03h15 HE
|
Biofrontera AG
Enrollment of 186 patients at 12 study sites in the U.S. startedPhase III trial completion for photodynamic therapy of superficial basal cell carcinoma expected in first half of 2020Filing for...